WinSanTor is the exclusive licensee of the intellectual property for our underlying technology–licensed from The University of Manitoba, University of California, San Diego, and The University of Toronto. We now have issued patents in Canada, China, India and the US, which include relatively broad patents that cover the entire class of compounds (e.g. the underlying pathway). We are awaiting hopefully similar results in Europe. We have additional patents that target WST-057 which, if issued, will expire after 2038. We are also developing intellectual property around other indications and other drugs. With our strong team of patent attorneys and former attorneys working with the company to manage our intellectual property, we have built a large fence around our technology and company.